Not Yet RecruitingPhase 1/2

Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy

United States16 participantsStarted 2026-04

Plain-language summary

The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years. All participants who have received at least one dose/injection of EG110A in a previous clinical study of EG110A will be asked to roll-over to this long-term follow-up study upon either early discontinuation from, or completion of, that study.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- All participants who received at least one dose/injection of EG110A in Study EG110A-001-01 and have prematurely discontinued or completed that study. Exclusion Criteria: * Participant plans to participate in another investigational gene therapy study * Participant has an uncontrolled intercurrent illness, any disorder, or current substance abuse that would limit compliance with study requirements in the opinion of the investigator

What they're measuring

Incidence of treatment emergent serious adverse events (TESAEs)

Timeframe: 5 years

Incidence of treatment emergent adverse events (TEAEs) including treatment emergent averse events of special interest (TEAESIs)

Timeframe: 5 years

Trial details

NCT IDNCT07227285

SponsorEG 427

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2031-04

Contact for this trial

Sandrine Zourbas, Ph.D.

33 (0)625622802 szourbas@eg427.com

View on ClinicalTrials.gov More Urinary Bladder, Overactive trials